Literature DB >> 26791237

A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma.

Tong Wang1, Fumou Sun1, Wei Xie1, Mingying Tang1, Hua He1, Xuelian Jia1, Xuemei Tian1, Min Wang2, Juan Zhang3.   

Abstract

MHC class I-related chain A (MICA) is a principal immunoligand of the natural killer (NK) cell receptor NK group 2, member D (NKG2D) and plays a key role in NK cell-mediated immune recognition. Shedding of MICA from tumor cells leads to immunosuppression. To reconstitute the immunosurveilance function of NK cells, we constructed a fusion protein rG7S-MICA and explored its potential anti-tumor activity against hepatocellular carcinoma (HCC). rG7S-MICA consists of human MICA and a single-chain antibody fragment (scFv) targeting the tumor-associated antigen cluster of differentiation 24 (CD24). In vitro, rG7S-MICA engaged both NK cells and CD24(+) human HCC cells, and triggered NK cell-mediated cytolysis. Furthermore, in CD24(+) HCC-bearing nude mice, rG7S-MICA specifically targeted to the tumor tissue, where it effectively recruited NK cells and induced the release of cytokines, and showed superior anti-tumor activity. In conclusion, rG7S-MICA provides a new approach for HCC-targeting immunotherapy and has attracting potentials for clinical applications.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Antibody fusion protein; CD24; Immunosurveillance; MICA; NK cells

Mesh:

Substances:

Year:  2016        PMID: 26791237     DOI: 10.1016/j.canlet.2016.01.001

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  13 in total

Review 1.  Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer.

Authors:  Nicole C Smits; Tiffany A Coupet; Claire Godbersen; Charles L Sentman
Journal:  Expert Opin Biol Ther       Date:  2016-06-09       Impact factor: 4.388

2.  Selective targeted delivery of doxorubicin via conjugating to anti-CD24 antibody results in enhanced antitumor potency for hepatocellular carcinoma both in vitro and in vivo.

Authors:  Zhaoxiong Ma; Hua He; Fumou Sun; Yao Xu; Xuequn Huang; Yuexing Ma; Hong Zhao; Yang Wang; Min Wang; Juan Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2017-05-23       Impact factor: 4.553

3.  Anti-hepatocarcinoma activity of TT-1, an analog of melittin, combined with interferon-α via promoting the interaction of NKG2D and MICA.

Authors:  Lan-Lan Wan; Da-Qi Zhang; Jin-Nan Zhang; Li-Qun Ren
Journal:  J Zhejiang Univ Sci B       Date:  2017-06       Impact factor: 3.066

4.  αVEGFR2-MICA fusion antibodies enhance immunotherapy effect and synergize with PD-1 blockade.

Authors:  Mingzhu Pan; Fei Wang; Lidi Nan; Siyu Yang; Jinyao Qi; Jiajun Xie; Shuai Shao; Hongyi Zou; Min Wang; Fumou Sun; Juan Zhang
Journal:  Cancer Immunol Immunother       Date:  2022-10-13       Impact factor: 6.630

5.  Tumor immunotherapy: New aspects of natural killer cells.

Authors:  Yangxi Li; Rui Sun
Journal:  Chin J Cancer Res       Date:  2018-04       Impact factor: 5.087

Review 6.  Cancer stem cells in hepatocellular carcinoma - from origin to clinical implications.

Authors:  Terence Kin-Wah Lee; Xin-Yuan Guan; Stephanie Ma
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-09-09       Impact factor: 46.802

Review 7.  Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancer.

Authors:  Matthias Peipp; Katja Klausz; Ammelie Svea Boje; Tobias Zeller; Stefan Zielonka; Christian Kellner
Journal:  Clin Exp Immunol       Date:  2022-07-22       Impact factor: 5.732

Review 8.  Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy.

Authors:  Hui Ding; Xi Yang; Yanzhang Wei
Journal:  Int J Mol Sci       Date:  2018-01-07       Impact factor: 5.923

9.  Control of Tumor Initiation by NKG2D Naturally Expressed on Ovarian Cancer Cells.

Authors:  Xin Cai; Andrea Caballero-Benitez; Mesfin M Gewe; Isaac C Jenkins; Charles W Drescher; Roland K Strong; Thomas Spies; Veronika Groh
Journal:  Neoplasia       Date:  2017-05-09       Impact factor: 5.715

10.  Engineering a high-affinity humanized anti-CD24 antibody to target hepatocellular carcinoma by a novel CDR grafting design.

Authors:  Fumou Sun; Tong Wang; Jiahao Jiang; Yang Wang; Zhaoxiong Ma; Zhaoting Li; Yue Han; Mingzhu Pan; Jialing Cai; Min Wang; Juan Zhang
Journal:  Oncotarget       Date:  2017-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.